mitomycin has been researched along with Glial Cell Tumors in 14 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of chemotherapy drug Mitomycin C (MMC) in combination with recombinant adeno-associated virus II (rAAV2) in cancer therapy was investigated, and the mechanism of MMC affecting rAAV2's bioactivity was also studied." | 5.39 | Effect and mechanism of Mitomycin C combined with recombinant adeno-associated virus type II against glioma. ( Deng, Y; Han, C; Lei, R; Ma, H; Qing, H; Rao, L; Wang, H; Xiang, J; Yang, Z; Zhang, L; Zhang, Y, 2013) |
| "Cytotoxic T lymphocytes (CTL) against autologous malignant brain tumor were generated in peripheral blood lymphoid cells (PBL) prepared from a patient with a malignant brain tumor by stimulation of the cultured PBL for 7 days with attenuated crossreactive malignant melanoma (MM2) cells pretreated with mitomycin C." | 3.69 | Induction of specific cytotoxic T lymphocytes against autologous brain tumor by crossreactive allo-tumor cell stimulation. ( Fujimoto, S; Kurisaka, M; Maeda, N; Mori, K; Saitoh, S, 1997) |
| "The effect of chemotherapy drug Mitomycin C (MMC) in combination with recombinant adeno-associated virus II (rAAV2) in cancer therapy was investigated, and the mechanism of MMC affecting rAAV2's bioactivity was also studied." | 1.39 | Effect and mechanism of Mitomycin C combined with recombinant adeno-associated virus type II against glioma. ( Deng, Y; Han, C; Lei, R; Ma, H; Qing, H; Rao, L; Wang, H; Xiang, J; Yang, Z; Zhang, L; Zhang, Y, 2013) |
| "Metronidazole, 1." | 1.27 | Feasibility study of combining metronidazole with chemotherapy. ( Bélanger, R; Crook, AF; Heringer, R; Hopkins, HS; Hugenholtz, H; Maroun, JA; Richard, MT; Stewart, DJ; Yan, RC; Young, V, 1983) |
| " Both dosage and releasing time can be adjusted." | 1.27 | [Treatment of malignant brain tumors with slowly releasing anticancer drug-polymer composites]. ( Himuro, H; Inoue, N; Kaetsu, I; Kitamura, K; Kubo, O; Sakairi, M; Tajika, T; Tajika, Y; Tohyama, T; Yoshida, M, 1986) |
| "In those with metastatic brain tumors, the median survival time was 280 days, 1-year survival rate 43." | 1.27 | [Clinical application of a sustained release anticancer pellet]. ( Aoyama, I; Handa, H; Hashi, K; Kamijyo, Y; Mori, K; Oda, Y; Okumura, T; Tokuriki, Y; Yamashita, J, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (35.71) | 18.7374 |
| 1990's | 5 (35.71) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kokoshka, JM | 1 |
| Ireland, CM | 1 |
| Barrows, LR | 1 |
| Ma, H | 1 |
| Zhang, Y | 1 |
| Wang, H | 1 |
| Han, C | 1 |
| Lei, R | 1 |
| Zhang, L | 1 |
| Yang, Z | 1 |
| Rao, L | 1 |
| Qing, H | 1 |
| Xiang, J | 1 |
| Deng, Y | 1 |
| Li, H | 1 |
| Liu, T | 1 |
| Chen, X | 2 |
| Xie, L | 1 |
| Chen, Y | 1 |
| Douglass, T | 1 |
| Jeffes, EW | 1 |
| Xu, Q | 1 |
| Williams, CC | 1 |
| Arpajirakul, N | 1 |
| Delgado, C | 1 |
| Kleinman, M | 1 |
| Sanchez, R | 1 |
| Dan, Q | 1 |
| Kim, RC | 1 |
| Wepsic, HT | 1 |
| Jadus, MR | 1 |
| Yuan, S | 1 |
| Wang, Y | 1 |
| Jiang, S | 1 |
| Yang, Y | 1 |
| Song, Y | 1 |
| Tu, C | 1 |
| Stewart, DJ | 1 |
| Maroun, JA | 1 |
| Young, V | 1 |
| Crook, AF | 1 |
| Hopkins, HS | 1 |
| Yan, RC | 1 |
| Richard, MT | 1 |
| Hugenholtz, H | 1 |
| Bélanger, R | 1 |
| Heringer, R | 1 |
| Saitoh, S | 1 |
| Kurisaka, M | 1 |
| Mori, K | 2 |
| Maeda, N | 1 |
| Fujimoto, S | 1 |
| Nitta, T | 1 |
| Nikkhah, G | 1 |
| Tonn, JC | 1 |
| Hoffmann, O | 1 |
| Kraemer, HP | 1 |
| Darling, JL | 1 |
| Schachenmayr, W | 1 |
| Schönmayr, R | 1 |
| Nakamura, O | 1 |
| Matsutani, M | 1 |
| Nomura, K | 1 |
| Takakura, K | 1 |
| Kawakami, K | 1 |
| Kawamoto, K | 1 |
| Oka, N | 1 |
| Kawamura, Y | 1 |
| Matsumura, H | 1 |
| Ito, T | 1 |
| Ohyama, A | 1 |
| Kubo, O | 1 |
| Himuro, H | 1 |
| Inoue, N | 1 |
| Tajika, Y | 1 |
| Tajika, T | 1 |
| Tohyama, T | 1 |
| Sakairi, M | 1 |
| Yoshida, M | 1 |
| Kaetsu, I | 1 |
| Kitamura, K | 1 |
| Ito, H | 1 |
| Hasegawa, T | 1 |
| Shoin, K | 1 |
| Hwang, WZ | 1 |
| Hayashi, M | 1 |
| Yamamoto, S | 1 |
| Miyazaki, I | 1 |
| Oda, Y | 1 |
| Kamijyo, Y | 1 |
| Okumura, T | 1 |
| Tokuriki, Y | 1 |
| Yamashita, J | 1 |
| Handa, H | 1 |
| Aoyama, I | 1 |
| Hashi, K | 1 |
1 review available for mitomycin and Glial Cell Tumors
| Article | Year |
|---|---|
[A history and prospect of adoptive immunotherapy against malignant glioma--past, now and future].
Topics: Brain Neoplasms; Glioma; Humans; Immunotherapy, Adoptive; Immunotoxins; Interleukin-2; Killer Cells, | 1992 |
13 other studies available for mitomycin and Glial Cell Tumors
| Article | Year |
|---|---|
Cell-based screen for identification of inhibitors of tubulin polymerization.
Topics: Animals; Brain Neoplasms; Bucladesine; Cell Differentiation; Drug Screening Assays, Antitumor; Forma | 1996 |
Effect and mechanism of Mitomycin C combined with recombinant adeno-associated virus type II against glioma.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Survival; Dependovirus; Genetic Therapy | 2013 |
A rare case of primary congenital glaucoma in combination with neurofibromatosis 1: a case report.
Topics: Alkylating Agents; Brain Neoplasms; Combined Modality Therapy; Glioma; Humans; Hydrophthalmos; Infan | 2015 |
Living T9 glioma cells expressing membrane macrophage colony-stimulating factor produce immediate tumor destruction by polymorphonuclear leukocytes and macrophages via a "paraptosis"-induced pathway that promotes systemic immunity against intracranial T9
Topics: Animals; Antibodies; Brain Neoplasms; Cell Death; Chemokines, CXC; Chemotactic Factors; Female; Free | 2002 |
[Study on chemosensitivity assay in vitro in the peripheral blood lymphocyte and the tumor cells].
Topics: Antineoplastic Agents; Brain Neoplasms; Doxorubicin; Drug Screening Assays, Antitumor; Glioma; Human | 2000 |
Feasibility study of combining metronidazole with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma, Sq | 1983 |
Induction of specific cytotoxic T lymphocytes against autologous brain tumor by crossreactive allo-tumor cell stimulation.
Topics: Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antigens, CD; Antigens, Neoplasm; Autoant | 1997 |
The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: Evaluation of patient- and drug-specific variables.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Survival; Colony-Forming Units Assay; Color | 1992 |
[Drug sensitivity test against malignant gliomas].
Topics: Animals; Antineoplastic Agents; Bleomycin; Doxorubicin; Drug Screening Assays, Antitumor; Glioma; Hu | 1990 |
[Flow cytometric studies of brain tumors--5: New sensitivity test of antineoplastic agents for brain tumors and its clinical application].
Topics: Animals; Antineoplastic Agents; Bleomycin; Brain Neoplasms; Cell Cycle; Cell Survival; Colony-Formin | 1986 |
[Treatment of malignant brain tumors with slowly releasing anticancer drug-polymer composites].
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Doxorubicin; Drug Implants; Dysge | 1986 |
[Necrotomy of brain stem glioma and local administration of anticancer agents].
Topics: Administration, Topical; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; B | 1985 |
[Clinical application of a sustained release anticancer pellet].
Topics: Antineoplastic Agents; Brain Neoplasms; Delayed-Action Preparations; Drug Administration Schedule; F | 1985 |